Sildenafil limits monocrotaline-induced pulmonary hypertension in rats through suppression of pulmonary vascular remodeling

Journal of Cardiovascular Pharmacology

Volumn 55, Issue 6, 2010, Pages 574-584

  Yen, Chia Hung ^a   Leu, Steve ^b   Lin, Yu Chun ^b   Kao, Ying Hsien ^d   Chang, Li Teh ^e   Chua, Sarah ^b   Fu, Morgan ^b   Wu, Chiung Jen ^b   Sun, Cheuk Kwan ^c   Yip, Hon Kan ^b  

^a NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d I SHOU UNIVERSITY   (Taiwan)

^e MEIHO UNIVERSITY   (Taiwan)

Author keywords

monocrotaline; pulmonary arterial hypertension; sildenafil

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CASPASE 3; CONNEXIN 43; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MESSENGER RNA; MONOCROTALINE; MYOSIN HEAVY CHAIN ALPHA; MYOSIN HEAVY CHAIN BETA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE C EPSILON; SILDENAFIL; SMAD1 PROTEIN; SMAD3 PROTEIN; SMAD5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; NOS3 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE; VENTRICULAR MYOSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HEART RIGHT VENTRICLE; LUNG ARTERY; LUNG BLOOD VESSEL; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; SYSTOLIC BLOOD PRESSURE; WESTERN BLOTTING; ANIMAL; ARTERIOLE; BLOOD VESSEL; CHEMICALLY INDUCED; DRUG EFFECTS; HYPERTENSION; LUNG; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT; VASCULARIZATION;

ANIMALS; ARTERIOLES; BLOOD VESSELS; CASPASE 3; CONNEXIN 43; HYPERTENSION; HYPERTENSION, PULMONARY; LUNG; MALE; MONOCROTALINE; NITRIC OXIDE SYNTHASE TYPE III; PIPERAZINES; PURINES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SULFONES; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR MYOSINS;

EID: 77953812679     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181d9f5f4     Document Type: Article

References (38)

1. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115:343-349.
2. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336: 111-117.
3. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation. 1989;80:1198-1206.
4. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet. 2003;361: 1533-1544.
5. Rubin LJ, Badesch DB. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med. 2005;143:282-292.
6. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet. 1998;352: 719-725.
7. Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med. 2009;361:1864-1871.
8. Anand IS, Prasad BA, Chugh SS, et al. Effects of inhaled nitric oxide and oxygen in high-altitude pulmonary edema. Circulation. 1998;98: 2441-2445.
9. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999;99:1197-1208.
10. Kalra L, Bone MF. Effect of nifedipine on physiologic shunting and oxygenation in chronic obstructive pulmonary disease. Am J Med. 1993; 94:419-423.
11. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132: 425-434.
12. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296-302.
13. Channick RN, Simonneau G, Sitbon O, et al. Effects of dual endothelinreceptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet. 2001;358:1119-1123. (Pubitemid 32971843)
14. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
15. Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8:47-52.
16. Goldenberg MM. Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. Clin Ther. 1998;20:1033-1048.
17. Ahn HS, Foster M, Cable M, et al. Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv Exp Med Biol. 1991;308:191-197.
18. Rabe KF, Tenor H, Dent G, et al. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol. 1994;266:L536-L543.
19. Shekerdemian LS, Ravn HB, Penny DJ. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med. 2002;165:1098-1102.
20. Zhao L, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxiainduced pulmonary hypertension. Circulation. 2001;104:424-428.
21. Itoh T, Nagaya N, Fujii T, et al. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med. 2004;169:34-38. (Pubitemid 38233886)
22. Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med. 2004;169:39-45.
23. Chang LT, Sun CK, Sheu JJ, et al. Cilostazol therapy attenuates monocrotaline-induced pulmonary arterial hypertension in rat model. Circ J. 2008;72:825-831.
24. Sun CK, Yuen CM, Kao YH, et al. Propylthiouracil attenuates monocrotaline-induced pulmonary arterial hypertension in rats. Circ J. 2009;73:1722-1730.
25. Yen CH, Lau YT. Vascular responses in male and female hypertensive rats with hyperhomocysteinemia. Hypertension. 2002;40:322-328.
26. Yen CH, Lau YT. 17beta-estradiol enhances aortic endothelium function and smooth muscle contraction in male spontaneously hypertensive rats. Clin Sci. 2004;106:541-546.
27. Long L, Crosby A, Yang X, et al. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation. 2009;119:566-576.
28. Kee HJ, Sohn IS, Nam KI, et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation. 2006;113:51-59.
29. Chen YM, Tu CJ, Hung KY, et al. Inhibition by pentoxifylline of TNFalpha- stimulated fractalkine production in vascular smooth muscle cells: evidence for mediation by NF-kappa B down-regulation. Br J Pharmacol. 2003;138:950-958.
30. Chen YM, Chiang WC, Lin SL, et al. Dual regulation of tumor necrosis factor-a-induced CCL2/monocyte chemoattractant protein-1 expression in vascular smooth muscle cells by nuclear factor-kB and activator protein-1: modulation by type III phosphodiesterase inhibition. J Pharmacol Exp Ther. 2004;309:978-986.
31. Hashimoto A, Miyakoda G, Hirose Y, et al. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis. 2006;189:350-357.
32. Uzzaman M, Honjo H, Takagishi Y, et al. Remodeling of gap junctional coupling in hypertrophied right ventricles of rats with monocrotalineinduced pulmonary hypertension. Circ Res. 2000;86:871-878.
33. Yeh HI, Lupu F, Dupont E, et al. Upregulation of connexin43 gap junctions between smooth muscle cells after balloon catheter injury in the rat carotid artery. Aterioscler Thromb Vasc Biol. 1997;17:3174-3184.
34. Shao PL, Chiu CC, Yuen CM, et al. Shock wave therapy effectively attenuates inflammation in rat carotid artery following endothelial denudation by balloon catheter. Cardiology. 2009;115:130-144.
35. Zhao L, Sebkhi A, Ali O, et al. Simvastatin and sildenafil combine to attenuate pulmonary hypertension. Eur Respir J. 2009;34:948-957.
36. Pepke-Zaba J, Gilbert C, Collings L, et al. Sildenafil improves healthrelated quality of life in patients with pulmonary arterial hypertension. Chest. 2008;133:183-189.
37. Lowenstein CJ, Dinerman JL, Snyder SH. Nitric oxide: a physiologic messenger. Ann Intern Med. 1994;120:227-237.
38. Rudic RD, Shesely EG, Maeda N, et al. Direct evidence for the importance of endothelium-derived nitric oxide vascular remodeling. J Clin Invest. 1998;101:731-736.